STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies* Note: Page numbers are those displayed in the top left/right corner of the submission pdf.

| | Item No | Recommendation | Page No. |
|------------------------|------------|---|----------------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in | Title page |
| | | the title or the abstract | |
| | | (b) Provide in the abstract an informative and balanced | 2 |
| | | summary of what was done and what was found | |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the | 4-5 |
| | | investigation being reported | |
| Objectives | 3 | State specific objectives, including any prespecified | 5 |
| | | hypotheses | |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 5-6 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including | 5, 6 & 9 |
| | | periods of recruitment, exposure, follow-up, and data | |
| | | collection | |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods | 5 |
| | | of selection of participants | |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential | 6-10 |
| | | confounders, and effect modifiers. Give diagnostic criteria, if | |
| | | applicable | |
| Data sources/ | 8 | For each variable of interest, give sources of data and details | 6-10 |
| measurement | | of methods of assessment (measurement). Describe | |
| | | comparability of assessment methods if there is more than one | |
| | | group | |
| Bias | 9 | Describe any efforts to address potential sources of bias | Potential bias |
| | | | discussed on |
| | | | page 16 |
| Study size | 10 | Explain how the study size was arrived at | 5 (pilot) |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the | 6-10 |
| | | analyses. If applicable, describe which groupings were chosen | |
| | | and why | 0.10 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to | 9-10 |
| | | control for confounding | 0.10 |
| | | (b) Describe any methods used to examine subgroups and | 9-10 |
| | | interactions (c) Explain how missing data were addressed | m/o |
| | | | n/a |
| | | (d) If applicable, describe analytical methods taking account | n/a |
| | | of sampling strategy (e) Describe any sensitivity analyses | n/a |
| D 14 | | (E) Describe any sensitivity analyses | 11/ ä |
| Results | 12 | (a) Domont numbers of individuals at said track to | £ 0 0 |
| Participants | 13 | (a) Report numbers of individuals at each stage of study—eg | 5 & 9 |
| | | numbers potentially eligible, examined for eligibility, | |
| | | confirmed eligible, included in the study, completing follow- | |

| | | (b) Give reasons for non-participation at each stage | 5 & 9 |
|-------------------|----|--|--------------------|
| | | (c) Consider use of a flow diagram | n/a |
| Descriptive data | 14 | (a) Give characteristics of study participants (eg demographic, | Table 1 |
| | | clinical, social) and information on exposures and potential | |
| | | confounders | |
| | | (b) Indicate number of participants with missing data for each | Table 1 |
| | | variable of interest | |
| Outcome data | 15 | Report numbers of outcome events or summary measures | 11 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder- | Table 2 |
| | | adjusted estimates and their precision (eg, 95% confidence | |
| | | interval). Make clear which confounders were adjusted for | |
| | | and why they were included | |
| | | (b) Report category boundaries when continuous variables | n/a |
| | | were categorized | |
| | | (c) If relevant, consider translating estimates of relative risk | n/a |
| | | into absolute risk for a meaningful time period | |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and | Table 3 |
| | | interactions, and sensitivity analyses | |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 13-14 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources | 16-17 |
| | | of potential bias or imprecision. Discuss both direction and | |
| | | magnitude of any potential bias | |
| Interpretation | 20 | Give a cautious overall interpretation of results considering | 14-17 |
| | | objectives, limitations, multiplicity of analyses, results from | |
| | | similar studies, and other relevant evidence | |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study | 17 (feasible to |
| | | results | conduct large- |
| | | | scale study) |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the | 18 |
| | | present study and, if applicable, for the original study on | |
| | | which the present article is based | |